Dr. Maged Aljahel
panellist
Consultant Of Internal medicine and Medical Oncology in King Salman bin Abdulaziz Medical city - Madinah
Associate Executive Director of Oncology & Hematology Center in King Salman bin Abdulaziz Medical city - Madinah
Vice President of the Saudi Oncology Society SOS
09:45 –10:30
Friday 3-5-2024 Day 1
Role of anthracyclines in early breast cancer
- When to omit anthracyclines in(neo) adjuvant therapy of HER2-negative breast cancer
When to use anthracyclines in (neo) adjuvant therapy of HER2-positive breast cancer
Moderator:
Dr. Meteeb Alfohaidi
Panel:
16:45-17:30
Friday 3-5-2024 Day 1
Transition from hormonal-based to chemotherapy in metastatic BC??
- Patients with early progression on CDK4-6 inhibitors: What is next??
- When to start ADCs/olaparib in patients who had visceral crisis?? Can be upfront??
- Any role of hormonal monotherapy after CDK4-6 inhibitors??
- Biomarkers to guide subsequent therapies
- Can we use one ADC after previous ADC??
Moderator: 
Dr. Ahmed Alfaraj
Panel:
